Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell linesSilvia La Monica, Roberta Alfieri|Journal of Experimental & Clinical Cancer Research|2017Cited by 89
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Alfieri|Journal of Experimental & Clinical Cancer Research|2019Cited by 70
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Roberta Alfieri|Molecular Cancer|2014Cited by 67
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET AmplificationSilvia La Monica, Roberta Alfieri|PLoS ONE|2013Cited by 49
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell linesRoberta Alfieri, Pier Giorgio Petronini|Molecular Cancer|2011Cited by 46